Mapping Advances Made With ADCs in Lung Cancer

Edwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

Luis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.

Yasushi Goto, MD, discusses primary efficacy findings from the phase 1 TROPION-Lung02 trial of datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy in patients with advanced non–small cell lung cancer.